Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback